About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

388.33 -2.94 (-0.75%)
Streaming Delayed Price Updated: 10:00 AM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
71 72 Next >
News headline image
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
News headline image
Amgen Unusual Options Activity ↗
 
Via Benzinga
News headline image
1 Dividend Growth Stock to Buy and Hold for 10 Years ↗
This company's payouts look safe. 
Via The Motley Fool
News headline image
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends ↗
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe. 
Via Talk Markets
News headline image
These Are The Best Dow Jones Stocks Of 2024 Thus Far ↗
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
News headline image
Can Amgen Stock Keep Trouncing the S&P 500? ↗
Amgen's market-beating ways are unlikely to evaporate any time soon. 
Via The Motley Fool
Topics Stocks
News headline image
Smart Money Is Betting Big In AMGN Options ↗
 
Via Benzinga
News headline image
Tech Is Consolidating And The Market’s Seeking New Leadership ↗
The tape tells the tale, just like it always does: The tech sector is clearly in consolidation mode right now. 
Via Talk Markets
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
News headline image
Where Will Amgen Be in 5 Years? ↗
Can Amgen be a market-beating stock? 
Via The Motley Fool
News headline image
Check Out What Whales Are Doing With AMGN ↗
 
Via Benzinga
News headline image
Expert Ratings For Amgen ↗
 
Via Benzinga
News headline image
Decoding Amgen's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on AMGN Options ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
News headline image
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks ↗
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
News headline image
3 Stocks to Buy as Ozempic Surges in Popularity ↗
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand. 
Via InvestorPlace
News headline image
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club ↗
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
News headline image
Where Will Amgen Be in 3 Years? ↗
The Amgen of 2027 could be much be larger than some investors expect. 
Via The Motley Fool
News headline image
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet ↗
The company is focusing on obesity treatment after its glaucoma drug failed. 
Via Investor's Business Daily
News headline image
Is Geron Stock a Buy Following Its First New Drug Approval? ↗
Find out if the high-flying biotech stock can keep on climbing higher. 
Via The Motley Fool
News headline image
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal ↗
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals. 
Via Benzinga
News headline image
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. ↗
There's probably a big enough pie here for everyone to get a slice. 
Via The Motley Fool
News headline image
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug ↗
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases. 
Via Benzinga
News headline image
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF ↗
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.